Navigation Links
High dosage brachytherapy obtains excellent results in head and neck tumors
Date:3/27/2009

This release is available in Spanish.

High-dosage perioperative brachytherapy (applied within the surgical process) obtains excellent results in the treatment of head and neck tumours, at the same time as reducing the period of radiation. These are the conclusions of research undertaken jointly by three Departments at the University of Navarra Hospital and which was published in the latest issue of Brachytherapy, official journal of the American Society of Brachytherapy.

The work describes the application of this new radiotherapy technique to 40 patients between 2000 and 2006. Given the size of the sample, the article is a description of the greatest number of patients treated with high-dosage brachytherapy for head and neck tumours in world medical literature. According to results, after a seven-year follow-up, the illness was controlled in 86% of the cases and the percentage of survival was 52%.

In concrete, the research focused on the treatment of tumours in the oral cavity, those affecting the tongue and the floor of the mouth, and those in the oropharyngeal region, such as tumours of the tonsils.

Involved in the study was a multidisciplinary team of seven specialists from three departments at the University of Navarra Hospital: the Radiotherapy Department, the Department of Oral and Maxillofacial Surgery and the Ear, Nose and Throat Department.

Intensifying radiation dosage

As is known, brachytherapy is a radiotherapy treatment involving the placing of radioactive sources within the tumour or nearby.

In the case in hand, the work analysed the application of brachytherapy as complementary post-surgery treatment, explained Doctor Rafael Martnez-Monge, Director of the Radiotherapy Department. Some cases of head and neck tumours require the application of radiotherapy after the surgical operation. Using this technique, they have managed to intensify the radiation dosage with the goal of reducing relapse rates.

In certain treatments, brachytherapy provides better end-result possibilities than conventional radiotherapy. The procedure enables the administration of doses that would not be easily achieved using other techniques, due to toxic effects, explained the specialist from the University of Navarra Hospital.

Two weeks of treatment less

Moreover, the use in brachytherapy of high dosages involves a series of benefits for the patient as regards the overall treatment. The great advantage, points out Doctor Martnez-Monge, is the reduction of total time. While conventional radiotherapy treatment lasted seven weeks, administering part of the radiation through brachytherapy can take two weeks less.

This technique also manages to reduce the time of radiation compared to treatment with low dosage brachytherapy. Thanks to the existence of new sources of radiation, the treatment is released in a matter of minutes. Before the patient under brachytherapy treatment carried the radioactive source for several days and, thus, had to be isolated in a lead-lined room, with limitations on visits and nursing care. With high-dosage brachytherapy, however, the patient is only radioactive during the actual administration of the treatment; as such, the rest of the time can be spent in a conventional room.

For the administration of this technique it is necessary to prepare the affected region during the surgical operation. On extirpating the tumour, the surgeon covers the surgery zone the area with greatest possibilities for relapse with a series of plastic tubes which are subsequently filled with radioactive material, the aim being to effect a highly selective and precise radiation. Brachytherapy is introduced through these tubes, one end of which appears at the surface of the skin, like a drainpipe, explained Doctor Rafael Martnez-Monge. These tubes are connected to a machine that administers the treatment according to a computer programme personalised for each patient, he added.

Application to other types of tumour

Apart from perioperative high-dosage brachytherapy treatment for head and neck tumours, the University of Navarra Hospital has been working on the application of this procedure to other oncological processes for a number of years. There are a number of studies under way on its use in gynaecological tumours and sarcomas, amongst others. Since 2000 about 400 patients, with different types of tumours, have been treated with this technique.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Vitamin Es lack of heart benefit linked to dosage
2. Capsugels Liquid Dosage Form Technology Utilized by Eight of the Top 10 Pharmaceutical Companies
3. FDA approves additional dosage strengths of Vyvanse
4. Attorney General Corbett Announces $36.7 Million Multi-State Settlement With CVS/Caremark in National Dosage-Switching Investigation
5. Comar, Inc. Launches AccuCup(TM) - A Printed Dosage Cup for Use in General and Pediatric Markets
6. Genetics May Help Fine-Tune Warfarin Dosage
7. Tools for more accurate dosage of drugs against HIV/AIDS and malaria
8. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
9. FDA Clears New Skin and Surface Treatment Applicator for Use With Xofts Axxent(R) Electronic Brachytherapy (eBx) System
10. R&D Magazine Selects Xoft Axxent(R) Electronic Brachytherapy System as Editors Choice Innovation Award Winner
11. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... Atlanta, GA (PRWEB) , ... ... ... information technology and security executive networking and relationship-marketing firm, announced today that ... for the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced that the company will provide alerting technology to Central Illinois Health ... awarded $1.7 million in federal funds as the sole sub-recipient participating with ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
Breaking Medicine Technology: